Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234736 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
A Phase 2 study, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05234736 is a Phase 2 study that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 10 participants.
The verdict
NCT05234736, a Phase 2 study, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
Interventions
- DRUG CBL-514
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05234736
The ClinicalTrials.gov registry entry for NCT05234736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBL-514 is the first listed.
NCT05234736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05234736 about?
NCT05234736 is a clinical study titled "A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers". This Phase 2 study will be an open-label and single course study to assess the safety, tolerability, PK and metabolite profile of CBL-514.
What is the current status of trial NCT05234736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-02-11. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT05234736?
The interventions under investigation include: CBL-514 (DRUG).
Who is sponsoring clinical trial NCT05234736?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.